Nonpharmacological lipoprotein apheresis reduces arterial inflammation in familial hypercholesterolemia

J Am Coll Cardiol. 2014 Oct 7;64(14):1418-26. doi: 10.1016/j.jacc.2014.01.088.

Abstract

Background: Patients with familial hypercholesterolemia (FH) are characterized by elevated atherogenic lipoprotein particles, predominantly low-density lipoprotein cholesterol (LDL-C), which is associated with accelerated atherogenesis and increased cardiovascular risk.

Objectives: This study used (18)F-fluorodeoxyglucose positron emission tomography ((18)FDG-PET) to investigate whether arterial inflammation is higher in patients with FH and, moreover, whether lipoprotein apheresis attenuates arterial wall inflammation in FH patients.

Methods: In total, 38 subjects were recruited: 24 FH patients and 14 normolipidemic controls. All subjects underwent FDG-PET imaging at baseline. Twelve FH patients who met the criteria for lipoprotein apheresis underwent apheresis procedures followed by a second FDG-PET imaging 3 days (range 1 to 4 days) after apheresis. Subsequently, the target-to-background ratio (TBR) of FDG uptake within the arterial wall was assessed.

Results: In FH patients, the mean arterial TBR was higher compared with healthy controls (2.12 ± 0.27 vs. 1.92 ± 0.19; p = 0.03). A significant correlation was observed between baseline arterial TBR and LDL-C (R = 0.37; p = 0.03) that remained significant after adjusting for statin use (β = 0.001; p = 0.02) and atherosclerosis risk factors (β = 0.001; p = 0.03). LDL-C levels were significantly reduced after lipoprotein apheresis (284 ± 118 mg/dl vs. 127 ± 50 mg/dl; p < 0.001). There was a significant reduction of arterial inflammation after lipoprotein apheresis (TBR: 2.05 ± 0.31 vs. 1.91 ± 0.33; p < 0.02).

Conclusions: The arterial wall of FH patients is characterized by increased inflammation, which is markedly reduced after lipoprotein apheresis. This lends support to a causal role of apoprotein B-containing lipoproteins in arterial wall inflammation and supports the concept that lipoprotein-lowering therapies may impart anti-inflammatory effects by reducing atherogenic lipoproteins.

Keywords: PET/CT imaging; atherosclerosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Arteries / pathology*
  • Atherosclerosis / blood
  • Blood Component Removal / methods*
  • Case-Control Studies
  • Cholesterol, LDL / blood
  • Cross-Sectional Studies
  • Female
  • Fluorodeoxyglucose F18 / chemistry
  • Humans
  • Hyperlipoproteinemia Type II / complications
  • Hyperlipoproteinemia Type II / therapy*
  • Inflammation / complications
  • Inflammation / therapy*
  • Lipoproteins / chemistry
  • Male
  • Middle Aged
  • Pilot Projects
  • Positron-Emission Tomography / methods
  • Prospective Studies
  • Risk Factors
  • Tomography, X-Ray Computed

Substances

  • Cholesterol, LDL
  • Lipoproteins
  • Fluorodeoxyglucose F18